File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0033-0620(96)80003-X
- Scopus: eid_2-s2.0-0030448012
- PMID: 8970575
- WOS: WOS:A1996VY11800003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Vascular endothelium: Vasoactive mediators
Title | Vascular endothelium: Vasoactive mediators |
---|---|
Authors | |
Issue Date | 1996 |
Publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/pcad |
Citation | Progress In Cardiovascular Diseases, 1996, v. 39 n. 3, p. 229-238 How to Cite? |
Abstract | In most blood vessels, the endothelium generates both vasodilator and growth-stabilizing mediators under normal physiological circumstances. The vasodilator influence of the endothelium modulates the vasoconstriction induced by adrenergic nerves, blood-borne substances, and local autacoids. Nitric oxide (NO) is a major endothelium-derived vasodilator, along with protacyclin. A third substance called endothelium-derived hyperpolarizing factors (EDHF) mediates vasodilatation in certain conduit arteries and in most resistance vessels. EDHF may be a cytochrome P-450 metabolite of arachidonic acid. NO acts mostly through an elevation of cyclic guanosine monophosphate in vascular smooth muscle, whereas prostacyclin stimulates adenylate cyclase. The mode of action of EDHF involves the activation of K+ channels. The multiplicity of the factors released by the endothelium, as well as the complexity of the interactions among these factors and those with other nonendothelial mediators, determine the extent of vasomotor control exerted locally by the endothelium. |
Persistent Identifier | http://hdl.handle.net/10722/171195 |
ISSN | 2023 Impact Factor: 5.6 2023 SCImago Journal Rankings: 1.669 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vanhoutte, PM | en_US |
dc.contributor.author | Mombouli, JV | en_US |
dc.date.accessioned | 2012-10-30T06:12:38Z | - |
dc.date.available | 2012-10-30T06:12:38Z | - |
dc.date.issued | 1996 | en_US |
dc.identifier.citation | Progress In Cardiovascular Diseases, 1996, v. 39 n. 3, p. 229-238 | en_US |
dc.identifier.issn | 0033-0620 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171195 | - |
dc.description.abstract | In most blood vessels, the endothelium generates both vasodilator and growth-stabilizing mediators under normal physiological circumstances. The vasodilator influence of the endothelium modulates the vasoconstriction induced by adrenergic nerves, blood-borne substances, and local autacoids. Nitric oxide (NO) is a major endothelium-derived vasodilator, along with protacyclin. A third substance called endothelium-derived hyperpolarizing factors (EDHF) mediates vasodilatation in certain conduit arteries and in most resistance vessels. EDHF may be a cytochrome P-450 metabolite of arachidonic acid. NO acts mostly through an elevation of cyclic guanosine monophosphate in vascular smooth muscle, whereas prostacyclin stimulates adenylate cyclase. The mode of action of EDHF involves the activation of K+ channels. The multiplicity of the factors released by the endothelium, as well as the complexity of the interactions among these factors and those with other nonendothelial mediators, determine the extent of vasomotor control exerted locally by the endothelium. | en_US |
dc.language | eng | en_US |
dc.publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/pcad | en_US |
dc.relation.ispartof | Progress in Cardiovascular Diseases | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Biological Factors - Physiology | en_US |
dc.subject.mesh | Endothelium, Vascular - Cytology - Drug Effects - Physiology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Nitric Oxide - Physiology | en_US |
dc.subject.mesh | Receptors, Endothelin - Drug Effects - Physiology | en_US |
dc.subject.mesh | Vasoconstrictor Agents - Pharmacology | en_US |
dc.subject.mesh | Vasodilator Agents - Pharmacology | en_US |
dc.title | Vascular endothelium: Vasoactive mediators | en_US |
dc.type | Article | en_US |
dc.identifier.email | Vanhoutte, PM:vanhoutt@hku.hk | en_US |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0033-0620(96)80003-X | en_US |
dc.identifier.pmid | 8970575 | - |
dc.identifier.scopus | eid_2-s2.0-0030448012 | en_US |
dc.identifier.volume | 39 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 229 | en_US |
dc.identifier.epage | 238 | en_US |
dc.identifier.isi | WOS:A1996VY11800003 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_US |
dc.identifier.scopusauthorid | Mombouli, JV=7004285772 | en_US |
dc.identifier.issnl | 0033-0620 | - |